IceCure Achieves Promising Results in Breast Cancer Cryoablation Study, According to

IceCure Achieves Promising Results in Breast Cancer Cryoablation Study, According to

© IceCure Medical Public Relations

CAESAREA, Israel – IceCure Medical Ltd. (NASDAQ: ICCM), an Israeli medical device company, today announced that its ICE3 clinical trial has shown promising results for the treatment of early-stage breast cancer. The study, which is the largest of its kind in the United States, investigating the effectiveness of liquid nitrogen-based cryoablation, observed a 96.39% recurrence rate among participants.

The ICE3 trial, which lasted more than a decade, tracked treatment outcomes in patients with early-stage, low-risk breast malignancies using IceCure’s ProSense® system. This minimally invasive technology offers an alternative to traditional surgery by freezing and destroying tumors. The final evaluation, which took place after a 5-year follow-up of the last patient, reported no adverse events or complications related to the device.

With these initial results, IceCure plans to submit the full data set to the U.S. Food and Drug Administration (FDA) in April 2024 for marketing authorization of ProSense®. Eyal Shamir, CEO of IceCure, said he is optimistic about the potential of ProSense® to become a viable alternative to lumpectomy, citing the system’s safety and effectiveness.

ProSense® is designed to improve value for both patients and providers by reducing recovery time, pain and surgical risks. The portability of the system and the use of liquid nitrogen allow procedures to be performed easily in the office. Currently, ProSense® is marketed worldwide for approved indications, including in the United States, Europe and China.

The announcement comes with a disclaimer that the results of historical scientific research and clinical trials do not guarantee future results.

This news is based on a press release from IceCure Medical.

This article was generated with the support of AI and reviewed by an editor. For more information, consult our General Terms and Conditions.

Source Reference

Latest stories